ATE319481T1 - Modifizierte saccharide, deren konjugate sowie deren herstellung - Google Patents

Modifizierte saccharide, deren konjugate sowie deren herstellung

Info

Publication number
ATE319481T1
ATE319481T1 AT03791149T AT03791149T ATE319481T1 AT E319481 T1 ATE319481 T1 AT E319481T1 AT 03791149 T AT03791149 T AT 03791149T AT 03791149 T AT03791149 T AT 03791149T AT E319481 T1 ATE319481 T1 AT E319481T1
Authority
AT
Austria
Prior art keywords
conjugates
linker
new
production
modified saccharides
Prior art date
Application number
AT03791149T
Other languages
German (de)
English (en)
Inventor
Aldo Giannozzi
Giovanni Averani
Francesco Norelli
Paolo Costantino
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Application granted granted Critical
Publication of ATE319481T1 publication Critical patent/ATE319481T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03791149T 2002-08-30 2003-09-01 Modifizierte saccharide, deren konjugate sowie deren herstellung ATE319481T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture

Publications (1)

Publication Number Publication Date
ATE319481T1 true ATE319481T1 (de) 2006-03-15

Family

ID=9943241

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03791149T ATE319481T1 (de) 2002-08-30 2003-09-01 Modifizierte saccharide, deren konjugate sowie deren herstellung

Country Status (16)

Country Link
US (2) US8895516B2 (enExample)
EP (1) EP1534342B1 (enExample)
JP (2) JP5268222B2 (enExample)
CN (2) CN1688343B (enExample)
AT (1) ATE319481T1 (enExample)
AU (1) AU2003260921B2 (enExample)
BR (1) BR0314089A (enExample)
CA (1) CA2497167C (enExample)
DE (1) DE60303961T2 (enExample)
DK (1) DK1534342T3 (enExample)
ES (1) ES2260682T3 (enExample)
GB (1) GB0220198D0 (enExample)
MX (1) MXPA05002315A (enExample)
NZ (1) NZ538703A (enExample)
RU (2) RU2005108992A (enExample)
WO (1) WO2004019992A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
US20070258986A1 (en) * 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
PL1885734T3 (pl) * 2005-05-06 2015-08-31 Novartis Ag Immunogeny dla szczepionek przeciwko Meningitidis-A
JP5792920B2 (ja) * 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US9475864B2 (en) 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
WO2011041003A2 (en) * 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
PT2493498T (pt) * 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
ES2930318T3 (es) 2014-02-14 2022-12-09 Pfizer Conjugados glucoproteicos inmunogénicos
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN107810273B (zh) * 2015-04-23 2022-09-27 西纳福克斯股份有限公司 用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
MX2018010920A (es) * 2016-03-15 2019-03-06 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos.
CN109890413B (zh) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
JP7680185B2 (ja) 2017-02-24 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎連鎖球菌多糖-タンパク質コンジュゲートの免疫原性の増強
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
MX2021010555A (es) * 2019-03-08 2022-04-06 Glaxosmithkline Biologicals Sa Derivados carbocíclicos y derivados conjugados de los mismos y su uso en vacunas.
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
DK0447171T3 (da) * 1990-03-15 1994-12-12 Tanabe Seiyaku Co Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf
CA2180149A1 (en) * 1993-12-28 1995-07-06 Michael Paul Deninno Steroidal glycosides
WO1995029927A2 (en) * 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
NZ331578A (en) 1997-01-21 2000-05-26 Pasteur Merieux Serums Vacc Polysaccharide-peptide-conjugates
DE69737298T2 (de) * 1997-08-08 2007-06-28 Dade Behring Marburg Gmbh Konjugate von polysacchariden und biomolekülen
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
ES2616180T3 (es) 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Also Published As

Publication number Publication date
WO2004019992A1 (en) 2004-03-11
JP2006511465A (ja) 2006-04-06
JP2012017342A (ja) 2012-01-26
RU2531909C2 (ru) 2014-10-27
EP1534342A1 (en) 2005-06-01
NZ538703A (en) 2006-09-29
ES2260682T3 (es) 2006-11-01
US20150166593A1 (en) 2015-06-18
DE60303961D1 (de) 2006-05-04
CN101863998B (zh) 2012-08-29
JP5268222B2 (ja) 2013-08-21
AU2003260921A1 (en) 2004-03-19
MXPA05002315A (es) 2005-06-08
BR0314089A (pt) 2005-11-16
US20060263390A1 (en) 2006-11-23
JP5314745B2 (ja) 2013-10-16
DE60303961T2 (de) 2006-10-26
AU2003260921B2 (en) 2008-03-06
DK1534342T3 (da) 2006-07-10
RU2008150551A (ru) 2010-06-27
CA2497167A1 (en) 2004-03-11
CN1688343A (zh) 2005-10-26
EP1534342B1 (en) 2006-03-08
CN1688343B (zh) 2010-09-08
US8895516B2 (en) 2014-11-25
GB0220198D0 (en) 2002-10-09
CA2497167C (en) 2011-07-12
CN101863998A (zh) 2010-10-20
RU2005108992A (ru) 2005-11-10

Similar Documents

Publication Publication Date Title
DE60303961D1 (de) Modifizierte saccharide, deren konjugate sowie deren herstellung
DE60323756D1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
WO2005030258A3 (en) Small molecule compositions and methods for increasing drug efficiency using compositions thereof
JP2005532287A5 (enExample)
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
WO2006120576A3 (en) Immunogens for meningitidis-a vaccines
EA200000327A2 (ru) Новые соединения аминотриазола, способ их получения и содержащие их фармацевтические композиции
MXPA03002779A (es) Derivados de glucopiranosiloxibencilbenceno y composiciones medicinales conteniendo los mismos.
ATE478841T1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
NO20076350L (no) Immunogen sammensetning
PT751144E (pt) Novos pro-farmacos antraciclinicos, metodo para preparacao e tambem a sua utilizacao em quimioterapia selectiva
IS6257A (is) Frumuviðloðunartálmar
EA200800822A1 (ru) Конъюгаты гидроксиалкилкрахмала и действующего вещества, полученные химическим лигированием через тиазолидин
WO2011010084A3 (en) Cyclosporin conjugates
DK1748791T3 (da) Neisseria Meningitidis IgtB LOS som hjælpestof
DE60128296D1 (de) Saccharid-Alkylenoxyderivate und Tinte
WO2004082581A3 (fr) Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
EP1775289A4 (en) NEW IMIDAZOLIDINE DERIVATIVES
WO2024238872A3 (en) Isoindolinone-glutarimide antibody conjugates, and uses thereof
ATE308540T1 (de) Antithrombosemittel
GB0501964D0 (en) Chemical compounds
DK1836151T3 (da) D-vitamin-receptormodulatorer
AU2002218422A1 (en) New desloratadine salts, process for their synthesis and pharmaceutical compositions thereof
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1534342

Country of ref document: EP

EEFA Change of the company name